EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias

Authors

Errata

This article is corrected by:

  1. Errata: Corrigendum Volume 17, Issue 2, 339, Article first published online: 13 January 2010

  • This is a Continuing Medical Education article, and can be found with corresponding questions on the internet at http://www.efns.org/content.php?pid=132. Certificates for correctly answering the questions will be issued by the EFNS.

  • This is a Continuing Medical Education article, and can be found with corresponding questions on the internet at http://www.efns.org/content.php?pid=132. Certificates for correctly answering the questions will be issued by the EFNS.

Hanne F. Harbo, MD, PhD. Department of Neurology, Ullevål, Oslo University Hospital, 0407 Oslo, Norway (tel.: +47 22118636/+47 99546680; fax: +47 23027455; e-mail: h.f.harbo@medisin.uio.no/hahb@uus.no).

Abstract

Background and purpose:  These EFNS guidelines on the molecular diagnosis of neurogenetic disorders are designed to provide practical help for the general neurologist to make appropriate use of molecular genetics in diagnosing neurogenetic disorders. Since the publication of the first two EFNS-guideline papers on the molecular diagnosis of neurological diseases in 2001, rapid progress has been made in this field, necessitating an updated series of guidelines.

Methods:  Literature searches were performed before expert members of the task force wrote proposals, which were discussed in detail until final consensus had been reached among all task force members.

Results and conclusion:  This paper provides updated guidelines for molecular diagnosis of Huntington’s disease, Parkinson’s disease and dystonias as well as a general introduction to the topic. Possibilities and limitations of molecular genetic diagnosis of these disorders are evaluated and recommendations are provided.

Ancillary